Compound Evidence File
#EC-2026-0907
T4 (Levothyroxine)
Filed under Oral Tablets. The bureau holds 65 laboratory returns for this compound from 28 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
28 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 6 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Bulk Peptide WholesaleCASE #VI-2026-0319 | X | 1 | 10.0 | 10.0 | 10.0 | 3 Jun 2025 | 3 Jun 2025 |
| Peptide TechnologiesCASE #VI-2026-0694 | X | 1 | 10.0 | 10.0 | 10.0 | 28 Mar 2025 | 28 Mar 2025 |
| HomopeptideCASE #VI-2026-0760 | A | 4 | 9.9 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 3 | 9.3 | 8.6 | 10.0 | 21 May 2026 | 21 May 2026 |
| Hunan Ruiwang Technology CenterCASE #VI-2026-0027 | X | 1 | 9.1 | 9.1 | 9.1 | 6 May 2025 | 6 May 2025 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 7 | 8.8 | 7.3 | 9.6 | 24 May 2026 | 24 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 6 | 8.6 | 7.0 | 9.5 | 24 May 2026 | 24 May 2026 |
| Shanghai Leader Peptide BiotechnologyCASE #VI-2026-0558 | X | 1 | 8.6 | 8.6 | 8.6 | 6 May 2025 | 6 May 2025 |
| ZZQ PeptidesCASE #VI-2026-0550 | X | 1 | 8.6 | 8.6 | 8.6 | 16 Mar 2025 | 16 Mar 2025 |
| Top PeptideCASE #VI-2026-0721 | X | 1 | 8.6 | 8.6 | 8.6 | 25 Apr 2025 | 25 Apr 2025 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 4 | 8.2 | 7.3 | 9.5 | 24 May 2026 | 24 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 3 | 7.9 | 7.5 | 8.3 | 25 May 2026 | 25 May 2026 |
| Pure Tested PeptidesCASE #VI-2026-0225 | X | 1 | 7.8 | 7.8 | 7.8 | 2 Apr 2025 | 2 Apr 2025 |
| Welon Peptide SolutionsCASE #VI-2026-0478 | X | 1 | 7.6 | 7.6 | 7.6 | 16 Mar 2025 | 16 Mar 2025 |
| SRY LabsCASE #VI-2026-0657 | X | 10 | 7.5 | 5.6 | 10.0 | 3 Jun 2025 | 17 May 2026 |
| Huaian Hanyou PeptideCASE #VI-2026-0297 | X | 1 | 7.5 | 7.5 | 7.5 | 24 Apr 2025 | 24 Apr 2025 |
| Haikou Mingheng TechnologyCASE #VI-2026-0250 | X | 1 | 7.1 | 7.1 | 7.1 | 14 Jan 2025 | 14 Jan 2025 |
| Mix PeptidesCASE #VI-2026-0699 | X | 2 | 6.6 | 5.0 | 8.2 | 16 Mar 2025 | 20 May 2026 |
| Kerisite Shenzhen InternationalCASE #VI-2026-0315 | X | 1 | 6.4 | 6.4 | 6.4 | 7 May 2025 | 7 May 2025 |
| YimeiCASE #VI-2026-0081 | X | 3 | 5.9 | 4.9 | 6.5 | 3 Jul 2025 | 24 May 2026 |
| Accelerate LabsCASE #VI-2026-0686 | X | 2 | 5.4 | 5.2 | 5.6 | 13 Feb 2025 | 19 Jan 2026 |
| Oasis PeptidesCASE #VI-2026-0404 | X | 1 | 5.4 | 5.4 | 5.4 | 25 Apr 2025 | 25 Apr 2025 |
| Hangzhou Youngpeptide Biotechnology HYBCASE #VI-2026-0347 | X | 1 | 5.4 | 5.4 | 5.4 | 2 Apr 2025 | 2 Apr 2025 |
| Amplified AminoCASE #VI-2026-0748 | X | 1 | 5.0 | 5.0 | 5.0 | 8 Jul 2025 | 8 Jul 2025 |
| Chimera PeptidesCASE #VI-2026-0260 | X | 1 | 4.0 | 4.0 | 4.0 | 24 Apr 2025 | 24 Apr 2025 |
| Coastal PeptidesCASE #VI-2026-0958 | X | 1 | 3.7 | 3.7 | 3.7 | 25 Apr 2025 | 25 Apr 2025 |
| Amino AmigosCASE #VI-2026-0061 | X | 1 | 3.3 | 3.3 | 3.3 | 28 Mar 2025 | 28 Mar 2025 |
Open any subject to view the batch-level evidence for T4 (Levothyroxine) alone.